NHERF1 inhibits proliferation of triple-negative breast cancer cells by suppressing GPER signaling

Wang,Yan; Peng,Zhiqiang; Meng,Ran; Tao,Tao; Wang,Qiqi; Zhao,Chunjuan; Liu,Hua; Song,Ran; Zheng,Junfang; Qin,Qiong; He,Junqi

doi:10.3892/or.2017.5649

NHERF1 inhibits proliferation of triple-negative breast cancer cells by suppressing GPER signaling

Authors:
- Yan Wang
- Zhiqiang Peng
- Ran Meng
- Tao Tao
- Qiqi Wang
- Chunjuan Zhao
- Hua Liu
- Ran Song
- Junfang Zheng
- Qiong Qin
- Junqi He
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, P.R. China
Published online on: May 18, 2017 https://doi.org/10.3892/or.2017.5649
Pages: 221-228

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

G protein-coupled estrogen receptor (GPER) signaling is activated in triple-negative breast cancer (TNBC); however, the detailed mechanisms of its regulation remain unclear. The present study aimed to elucidate the molecular mechanisms involved in GPER activation in TNBC. In MDA-MB-231 cells, a TNBC cell line, NHERF1 interaction with GPER was verified by co-immunoprecipitation and immunofluorescent staining assays. Overexpression of NHERF1 in MDA-MB-231 cells inhibited GPER-mediated proliferation and phosphorylation of ERK1/2 and Akt. Furthermore, NHERF1 expression levels were negatively correlated with the gene signatures of GPER activation, ERK1/2 and Akt signaling, and cell proliferation in early stage of TNBC tumors from the TCGA data set. Taken together, NHERF1 inhibited the activation of GPER-mediated signaling and suppressed the proliferation of triple-negative breast cancer cells. Loss of NHERF1 expression may play a pivotal role in the early stage of TNBC carcinogenesis.

View Figures

View References

1	Bianchini G, Balko JM, Mayer IA, Sanders ME and Gianni L: Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
2	Collignon J, Lousberg L, Schroeder H and Jerusalem G: Triple-negative breast cancer: Treatment challenges and solutions. Breast Cancer (Dove Med Press). 8:93–107. 2016.PubMed/NCBI
3	Kalimutho M, Parsons K, Mittal D, López JA, Srihari S and Khanna KK: Targeted therapies for triple-negative breast cancer: Combating a stubborn disease. Trends Pharmacol Sci. 36:822–846. 2015. View Article : Google Scholar : PubMed/NCBI
4	Prossnitz ER and Barton M: Estrogen biology: New insights into GPER function and clinical opportunities. Mol Cell Endocrinol. 389:71–83. 2014. View Article : Google Scholar : PubMed/NCBI
5	Steiman J, Peralta EA, Louis S and Kamel O: Biology of the estrogen receptor, GPR30, in triple negative breast cancer. Am J Surg. 206:698–703. 2013. View Article : Google Scholar : PubMed/NCBI
6	Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M and Picard D: Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 28:523–532. 2009. View Article : Google Scholar : PubMed/NCBI
7	Girgert R, Emons G and Gründker C: Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: Possible application in targeted therapy. Breast Cancer Res Treat. 134:199–205. 2012. View Article : Google Scholar : PubMed/NCBI
8	Yu T, Liu M, Luo H, Wu C, Tang X, Tang S, Hu P, Yan Y, Wang Z and Tu G: GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells. J Steroid Biochem Mol Biol. 143:392–403. 2014. View Article : Google Scholar : PubMed/NCBI
9	Girgert R, Emons G and Gründker C: Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol. BMC Cancer. 14:9352014. View Article : Google Scholar : PubMed/NCBI
10	Lappano R, Pisano A and Maggiolini M: GPER function in breast cancer: An Overview. Front Endocrinol (Lausanne). 5:662014.PubMed/NCBI
11	Hung AY and Sheng M: PDZ domains: Structural modules for protein complex assembly. J Biol Chem. 277:5699–5702. 2002. View Article : Google Scholar : PubMed/NCBI
12	Meng R, Qin Q, Xiong Y, Wang Y, Zheng J, Zhao Y, Tao T, Wang Q, Liu H, Wang S, et al: NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer. Oncotarget. 7:54983–54997. 2016.PubMed/NCBI
13	Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G and Georgescu MM: PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene. 31:1264–1274. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hayashi Y, Molina JR, Hamilton SR and Georgescu MM: NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia. 12:1013–1022. 2010. View Article : Google Scholar : PubMed/NCBI
15	Bellizzi A, Malfettone A, Cardone RA and Mangia A: NHERF1/EBP50 in breast cancer: Clinical perspectives. Breast Care (Basel). 5:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
16	Song J, Bai J, Yang W, Gabrielson EW, Chan DW and Zhang Z: Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer. Histopathology. 51:40–53. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ediger TR, Kraus WL, Weinman EJ and Katzenellenbogen BS: Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. Endocrinology. 140:2976–2982. 1999. View Article : Google Scholar : PubMed/NCBI
18	Stemmer-Rachamimov AO, Wiederhold T, Nielsen GP, James M, Pinney-Michalowski D, Roy JE, Cohen WA, Ramesh V and Louis DN: NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol. 158:57–62. 2001. View Article : Google Scholar : PubMed/NCBI
19	Yao W, Feng D, Bian W, Yang L, Li Y, Yang Z, Xiong Y, Zheng J, Zhai R and He J: EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation. Amino Acids. 43:2027–2035. 2012. View Article : Google Scholar : PubMed/NCBI
20	Saponaro C, Malfettone A, DellEndice TS, Brunetti AE, Achimas-Cadariu P, Paradiso A and Mangia A: The prognostic value of the Na+/H+ exchanger regulatory factor 1 (NHERF1) protein in cancer. Cancer Biomark. 14:177–184. 2014. View Article : Google Scholar : PubMed/NCBI
21	Dai JL, Wang L, Sahin AA, Broemeling LD, Schutte M and Pan Y: NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene. 23:8681–8687. 2004. View Article : Google Scholar : PubMed/NCBI
22	Barton M: Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER. Steroids. 111:37–45. 2016. View Article : Google Scholar : PubMed/NCBI
23	Jacenik D, Cygankiewicz AI and Krajewska WM: The G protein-coupled estrogen receptor as a modulator of neoplastic transformation. Mol Cell Endocrinol. 429:10–18. 2016. View Article : Google Scholar : PubMed/NCBI
24	Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM and Sabo E: Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res. 12:6359–6366. 2006. View Article : Google Scholar : PubMed/NCBI
25	Srivastava DP and Evans PD: G-protein oestrogen receptor 1Trials and tribulations of a membrane oestrogen receptor. J Neuroendocrinol. 25:1219–1230. 2013. View Article : Google Scholar : PubMed/NCBI
26	Weißenborn C, Ignatov T, Ochel HJ, Costa SD, Zenclussen AC, Ignatova Z and Ignatov A: GPER functions as a tumor suppressor in triple-negative breast cancer cells. J Cancer Res Clin Oncol. 140:713–723. 2014. View Article : Google Scholar : PubMed/NCBI
27	Wei W, Chen ZJ, Zhang KS, Yang XL, Wu YM, Chen XH, Huang HB, Liu HL, Cai SH, Du J, et al: The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. Cell Death Dis. 5:e14282014. View Article : Google Scholar : PubMed/NCBI
28	Pan Y, Wang L and Dai JL: Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1). Breast Cancer Res. 8:R632006. View Article : Google Scholar : PubMed/NCBI
29	Ardura JA and Friedman PA: Regulation of G protein-coupled receptor function by Na+/H+ exchange regulatory factors. Pharmacol Rev. 63:882–900. 2011. View Article : Google Scholar : PubMed/NCBI
30	Lazar CS, Cresson CM, Lauffenburger DA and Gill GN: The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell. 15:5470–5480. 2004. View Article : Google Scholar : PubMed/NCBI
31	Filardo EJ: Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 80:231–238. 2002. View Article : Google Scholar : PubMed/NCBI